AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
www_NN
._.
com_NN
113_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
2002_CD
,_,
under_IN
US_FPP1
GAAP_NN
,_,
goodwill_NN
was_VBD [PASS]
required_VBN [SUAV]
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
accounting_VBG [WZPRES]
principles_NN
to_TO
be_VB [PASS]
capitalized_VBN
and_PHC
amortised_VBN
._.
Now_DPAR
,_,
instead_CONJ
There_EX
are_VPRT
four_CD
main_JJ
differences_NN
between_PIN
of_PIN
being_VBG [PASS]
amortised_VBN
,_,
goodwill_NN
is_VPRT [PASS]
tested_VBN
current_JJ
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
in_PIN
The_DT
accompanying_VBG
consolidated_JJ
financial_JJ
annually_RB
for_PIN
impairment_NOMZ
._.
Amortisation_NOMZ
accounting_GER
for_PIN
pension_NN
costs_NN
:_:
statements_NOMZ
included_VBD
in_PIN
this_DEMO
Annual_JJ
Report_NN
are_VPRT [PASS]
charged_VBN
under_IN
UK_NN
GAAP_NN
is_VPRT [PASS]
added_VBN [PUBV]
back_RB
in_PIN
prepared_JJ
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
._.
the_DT
reconciliation_NOMZ
of_PIN
net_JJ
income_NN
._.
The_DT
i_FPP1
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
measurements_NOMZ
of_PIN
plan_NN
Certain_NN
significant_JJ
differences_NN
between_PIN
UK_NN
intangible_JJ
recognized_VBN [PRIV]
as_IN
assembled_VBN
assets_NN
and_PHC
obligations_NOMZ
to_TO
be_VB [PASS]
made_VBN
as_IN
at_PIN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
which_WDT [WHSUB]
affect_VPRT
workforce_NN
has_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
as_IN
goodwill_NN
._.
the_DT
date_NN
of_PIN
the_DT
financial_JJ
statements_NOMZ
or_CC
a_DT
AstraZenecas_NN
net_JJ
income_NN
and_PHC
shareholders_NN
date_NN
not_XX0
more_EMPH
than_PIN
three_CD
months_NN
prior_RB
to_PIN
equity_NOMZ
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Identifiable_JJ
intangible_JJ
assets_NN
,_,
which_WDT [SERE]
principally_RB
that_DEMO
date_NN
._.
Under_IN
UK_NN
GAAP_NN
,_,
calculations_NOMZ
include_VPRT
patents_NN
,_,
know-how_NN
and_PHC
product_NN
may_POMD
be_VB [PASS]
based_VBN
on_PIN
the_DT
results_NN
of_PIN
the_DT
latest_JJ
Purchase_NN
accounting_GER
adjustments_NOMZ
registrations_NOMZ
,_,
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
actuarial_JJ
valuation_NOMZ
:_:
Under_IN
UK_NN
GAAP_NN
the_DT
merger_NN
of_PIN
Astra_NN
and_CC
estimated_VBN [PRIV]
useful_JJ
lives_NN
which_WDT [WHSUB]
vary_VPRT
between_PIN
5_CD
Zeneca_NN
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
merger_NN
of_PIN
years_NN
and_CC
20_CD
years_NN
with_PIN
a_DT
weighted_JJ
average_JJ
ii_NN
US_FPP1
GAAP_NN
mandates_VPRT
a_DT
particular_JJ
actuarial_JJ
equals_VPRT
pooling-of-interests_NN
._.
Under_IN
US_FPP1
life_NN
of_PIN
approximately_RB
13_CD
years_NN
._.
method_NN
the_DT
projected_VBN
unit_NN
credit_NN
GAAP_NN
the_DT
merger_NN
was_VBD [PASS]
accounted_VBN
for_PIN
as_IN
the_DT
method_NN
and_CC
requires_VPRT [SUAV]
that_THVC
each_QUAN
acquisition_NOMZ
of_PIN
Astra_NN
by_PIN
Zeneca_NN
using_VBG [WZPRES]
At_PIN
31_CD
December_NN
2002_CD
and_CC
2001_CD
,_,
significant_JJ
assumption_NOMZ
necessary_JJ
to_TO
purchase_VB
accounting_GER
._.
Under_IN
purchase_NN
shareholders_NN
equity_NOMZ
includes_VPRT
capitalized_JJ
determine_VB [SUAV] [PRIV]
annual_JJ
pension_NN
cost_NN
reflects_VPRT [PRIV]
accounting_GER
,_,
the_DT
cost_NN
of_PIN
the_DT
investment_NOMZ
is_VPRT
goodwill_NN
of_PIN
$_$
13,600_CD
m_NN
and_CC
$_$
12,169_CD
m_NN [BEMA]
best_JJ
estimates_NN
solely_RB
with_PIN
regard_NN
to_PIN
that_DEMP
calculated_VBN [PRIV]
at_PIN
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
respectively_RB
net_JJ
of_PIN
amortisation_NOMZ
and_CC
individual_JJ
assumption_NOMZ
._.
UK_NN
GAAP_NN
does_EMPH
issued_VBN
together_RB
with_PIN
other_JJ
incidental_JJ
costs_NN
impairment_NOMZ
of_PIN
$_$
2,383_CD
m_NN
and_CC
$_$
2,180_CD
m_NN
and_CC
not_XX0
mandate_VB
a_DT
particular_JJ
method_NN
,_,
but_CC
and_CC
the_DT
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
acquired_VBN
capitalized_JJ
identifiable_JJ
intangible_JJ
assets_NN
of_PIN
requires_VPRT [SUAV]
that_THVC
the_DT
method_NN
and_PHC
entity_NOMZ
are_VPRT [PASS]
recorded_VBN
at_PIN
fair_JJ
value_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
$_$
9,433_CD
m_NN
and_CC
$_$
9,789_CD
m_NN [BEMA]
respectively_RB
net_PRED
of_PIN
assumptions_NOMZ
taken_VBN
as_IN
a_DT
whole_JJ
should_NEMD
be_VB [BEMA]
the_DT
fair_JJ
value_NN
exercise_NN
,_,
increases_NN
in_PIN
the_DT
values_NN
amortisation_NOMZ
and_PHC
impairment_NOMZ
of_PIN
$_$
4,566_CD
m_NN
and_CC
compatible_JJ
and_PHC
lead_JJ
to_PIN
the_DT
actuarys_NN
best_JJ
of_PIN
Astras_NN
tangible_JJ
fixed_VBN
assets_NN
and_PHC
inventory_NN
$_$
3,475_CD
m._FW
Goodwill_NN
on_PIN
businesses_NOMZ
disposed_VBN
estimate_NN
of_PIN
the_DT
cost_NN
of_PIN
providing_VBG
the_DT
were_VBD [PASS]
recognized_VBN [PRIV]
and_PHC
values_VPRT
attributed_VBN
to_PIN
their_TPP3
of_PIN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
gain_NN
or_CC
loss_NN
on_PIN
disposal_NN
._.
benefits_NN
promised_VBD [PUBV]
:_:
in-process_JJ
research_NN
and_PHC
development_NOMZ
,_,
existing_VBG
products_NN
and_CC
assembled_VBD
work_NN
force_NN
,_,
On_PIN
disposal_NN
of_PIN
a_DT
business_NOMZ
,_,
the_DT
gain_NN
or_CC
loss_NN
iii_NN
under_IN
US_FPP1
GAAP_NN
,_,
a_DT
negative_JJ
pension_NN
cost_NN
together_RB
with_PIN
appropriate_JJ
deferred_VBN
taxation_NOMZ
under_IN
US_FPP1
GAAP_NN
may_POMD
differ_VB
from_PIN
that_DEMO
under_IN
may_POMD
arise_VB
where_RB
a_DT
significant_JJ
effects_NN
._.
The_DT
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
UK_NN
GAAP_NN
due_JJ
principally_RB
to_PIN
goodwill_NN
unrecognised_JJ
net_JJ
asset_NN
or_CC
gain_NN
exists_VPRT
at_PIN
investment_NOMZ
and_CC
the_DT
fair_JJ
value_NN
of_PIN
the_DT
assets_NN
capitalized_VBN
and_PHC
amortised_VBN
,_,
together_RB
with_PIN
the_DT
the_DT
time_NN
of_PIN
implementation_NOMZ
._.
This_DEMP
is_VPRT
and_CC
liabilities_NOMZ
of_PIN
Astra_NN
was_VBD [PASS]
recorded_VBN
as_IN
appropriate_JJ
share_NN
of_PIN
other_JJ
differences_NN
required_VBN [SUAV]
to_TO
be_VB [PASS]
amortised_VBN
on_PIN
a_DT
straight-line_JJ
goodwill_NN
._.
The_DT
amount_NN
allocated_VBN [WZPAST]
to_PIN
in-process_JJ
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
basis_NN
over_IN
the_DT
average_JJ
remaining_VBG
service_NN
research_NN
and_PHC
development_NOMZ
was_VBD
,_,
as_IN
required_VBN [SUAV]
recognized_VBN [PRIV]
previously_TIME
._.
Under_IN
UK_NN
GAAP_NN
,_,
by_PIN
US_FPP1
GAAP_NN
,_,
expensed_VBD
immediately_TIME
in_PIN
the_DT
AstraZenecas_NN
policy_NN
is_VPRT
not_XX0
to_TO
recognize_VB [PRIV]
first_JJ
reporting_GER
period_NN
after_IN
the_DT
business_NOMZ
Capitalisation_NOMZ
of_PIN
interest_NN
pension_NN
credits_NN
in_PIN
its_PIT
financial_JJ
statements_NOMZ
combination_NOMZ
._.
Fair_NN
value_NN
adjustments_NOMZ
to_PIN
the_DT
AstraZeneca_NN
does_VPRT
not_XX0
capitalize_VB
interest_NN
in_PIN
its_PIT
unless_COND
a_DT
refund_NN
of_PIN [STPR]
,_,
or_CC
reduction_NOMZ
in_PIN [STPR]
,_,
recorded_VBN
amount_NN
of_PIN
inventory_NN
were_VBD [PASS]
expensed_VBN
financial_JJ
statements_NOMZ
._.
US_FPP1
GAAP_NN
requires_VPRT [SUAV] [THATD]
contributions_NOMZ
is_VPRT [BEMA]
likely_PRED
:_:
and_ANDC
in_PIN
the_DT
period_NN
the_DT
inventory_NN
was_VBD [PASS]
utilised_VBN
._.
interest_NN
incurred_VBN
as_IN
part_NN
of_PIN
the_DT
cost_NN
of_PIN
Additional_JJ
amortisation_NOMZ
and_PHC
depreciation_NOMZ
have_VPRT
constructing_VBG
fixed_VBN
assets_NN
to_TO
be_VB [PASS]
capitalized_VBN
iv_NN
under_IN
US_FPP1
GAAP_NN
,_,
a_DT
minimum_JJ
pension_NN
also_RB
been_VBN [PASS]
recorded_VBN
in_PIN
respect_NN
of_PIN
the_DT
fair_JJ
value_NN
and_CC
amortised_VBN
over_IN
the_DT
life_NN
of_PIN
the_DT
asset_NN
._.
liability_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
through_PIN
other_JJ
adjustments_NOMZ
to_PIN
tangible_JJ
and_PHC
intangible_JJ
assets_NN
comprehensive_JJ
income_NN
in_PIN
certain_JJ
and_CC
the_DT
resulting_VBG
goodwill_NN
._.
Dividends_NN
circumstances_NN
when_RB
there_EX
is_VPRT
a_DT
deficit_NN
of_PIN
Under_IN
UK_NN
GAAP_NN
Ordinary_NN
Share_NN
dividends_NN
plan_VPRT
assets_NN
relative_JJ
to_PIN
the_DT
projected_VBN
In_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
proposed_VBN [SUAV] [WZPAST]
are_VPRT [PASS]
provided_VBN
for_PIN
in_PIN
the_DT
year_NN
in_PIN
benefits_NN
obligation_NOMZ
._.
Under_IN
UK_NN
GAAP_NN
,_,
prepared_VBN
under_IN
UK_NN
GAAP_NN
,_,
goodwill_NN
arising_VBG [WZPRES]
on_PIN
respect_NN
of_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [BYPA]
recommended_VBN [SUAV]
by_PIN
there_EX
is_VPRT
no_SYNE
such_JJ
requirement_NOMZ
._.
acquisitions_NOMZ
made_VBD
prior_RB
to_PIN
1_CD
January_NN
1998_CD
the_DT
Board_NN
of_PIN
Directors_NN
for_PIN
approval_NN
by_PIN
the_DT
accounted_VBN
for_PIN
under_IN
the_DT
purchase_NN
method_NN
shareholders_NN
._.
Under_IN
US_FPP1
GAAP_NN
such_JJ
has_VPRT [PEAS]
been_VBN [PASS]
eliminated_VBN
against_PIN
shareholders_NN
dividends_NN
are_VPRT [PASS]
not_XX0
provided_VBN
for_PIN
until_IN
declared_VBN [PUBV]
equity_NOMZ
._.
Under_IN
the_DT
requirements_NOMZ
of_PIN
UK_NN
by_PIN
the_DT
Board_NN
._.
Financial_NN
Reporting_GER
Standard_NN
10_CD
Goodwill_NN
and_PHC
Intangible_NN
Assets_NN
,_,
goodwill_NN
on_PIN
Deferred_JJ
taxation_NOMZ
acquisitions_NOMZ
made_VBN
after_IN
1_CD
January_NN
1998_CD
is_VPRT [BEMA]
Deferred_JJ
taxation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
a_DT
full_JJ
liability_NOMZ
capitalized_VBN
and_PHC
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
basis_NN
under_IN
US_FPP1
GAAP_NN
,_,
which_WDT [SERE]
permits_VPRT
useful_JJ
life_NN
which_WDT [WHSUB]
is_VPRT [SPAU] [PASS]
generally_RB
presumed_VBN [PRIV]
not_XX0
to_TO
deferred_VBN
tax_NN
assets_NN
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
if_COND
their_TPP3
exceed_VPRT
20_CD
years_NN
._.
UK_NN
GAAP_NN
requires_VPRT [SUAV]
that_THVC
on_PIN
realisation_NOMZ
is_VPRT [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
more_EMPH
likely_PRED
than_PIN
subsequent_JJ
disposal_NN
or_CC
termination_NOMZ
of_PIN
a_DT
not_XX0
._.
Under_IN
current_JJ
UK_NN
GAAP_NN
,_,
full_JJ
provision_NN
is_VPRT [SPAU] [PASS]
previously_TIME
acquired_VBN
business_NOMZ
,_,
any_QUAN
goodwill_NN
also_RB
made_VBD
although_CONC
there_EX
are_VPRT
a_DT
number_NN
of_PIN
previously_TIME
taken_VBN
directly_RB
to_PIN
shareholders_NN
different_JJ
bases_NN
on_PIN
which_WDT [PIRE]
this_DEMO
calculation_NOMZ
is_VPRT
equity_NOMZ
is_VPRT [SPAU] [PASS]
then_RB
charged_VBN
in_PIN
the_DT
income_NN
made_VBN
,_,
eg_CONJ
rolled_VBD
over_IN
capital_NN
gains_NN
._.
statement_NOMZ
against_PIN
the_DT
profit_NN
or_CC
loss_NN
on_PIN
disposal_NN
or_CC
termination_NOMZ
._.
Up_IN
until_IN
1_CD
January_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
www_NN
._.
com_NN
114_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
the_DT
income_NN
statement_NOMZ
in_PIN
subsequent_JJ
periods_NN
comprise_VPRT
current_JJ
asset_NN
investments_NOMZ
held_VBD [PRIV]
as_IN
accounting_GER
principles_NN
continued_VBD
until_IN
all_QUAN
disposal_NN
obligations_NOMZ
and_CC
readily_RB
disposable_JJ
stores_NN
of_PIN
value_NN
._.
Under_IN
commitments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
completed_VBN
._.
95_CD
cash_NN
equivalents_NN
,_,
comprising_VBG
Restructuring_GER
costs_NN
short_JJ
term_NN
highly_AMP
liquid_JJ
investments_NOMZ
,_,
generally_RB
Under_IN
UK_NN
GAAP_NN
,_,
provisions_NN
are_VPRT [PASS]
made_VBN
for_PIN
Current_JJ
assets_NN
and_PHC
liabilities_NOMZ
with_PIN
original_JJ
maturities_NOMZ
of_PIN
three_CD
months_NN
or_CC
less_JJ
,_,
restructuring_VBG
costs_NN
once_TIME
a_DT
detailed_JJ
formal_JJ
In_PIN
the_DT
Groups_NN
financial_JJ
statements_NOMZ
prepared_VBN [WZPAST]
are_VPRT [PASS]
grouped_VBN
together_RB
with_PIN
cash_NN
:_:
short_JJ
term_NN
plan_NN
is_VPRT [BEMA]
in_PIN
place_NN
and_CC
valid_JJ
expectations_NOMZ
have_VPRT
under_IN
UK_NN
GAAP_NN
,_,
no_SYNE
cost_NN
is_VPRT [PASS]
accrued_VBN
for_PIN
the_DT
borrowings_GER
repayable_JJ
on_PIN
demand_NN
would_PRMD
not_XX0
been_VBN [PASS]
raised_VBN
in_PIN
those_DEMP
affected_VBN
that_DEMO
the_DT
share_NN
options_NOMZ
awarded_VBN [WZPAST]
to_PIN
employees_NN
under_IN
be_VB [PASS]
included_VBN
within_PIN
cash_NN
and_PHC
cash_NN
equivalents_NN
restructuring_VBG [WZPRES]
will_PRMD
be_VB [PASS]
carried_VBN
out_PIN [STPR]
._.
US_FPP1
GAAP_NN
the_DT
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
and_PHC
movements_NOMZ
on_PIN
those_DEMO
borrowings_GER
would_PRMD
requires_VPRT [SUAV]
a_DT
number_NN
of_PIN
specific_JJ
criteria_NN
to_TO
be_VB
Scheme_NN
,_,
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
be_VB [PASS]
included_VBN
in_PIN
financing_GER
activities_NOMZ
._.
met_VBN
before_IN
such_JJ
costs_NN
can_POMD
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
Plan_NN
,_,
and_ANDC
the_DT
AstraZeneca_NN
Savings-Related_NN
an_DT
expense_NN
._.
Among_PIN
these_DEMP
are_VPRT [BEMA]
the_DT
Share_NN
Option_NOMZ
Scheme_NN
as_IN
the_DT
exercise_NN
price_NN
is_VPRT [BEMA]
New_JJ
accounting_GER
standards_NN
adopted_VBN
requirements_NOMZ
that_TOBJ
the_DT
costs_NN
incurred_VBN [WZPAST]
are_VPRT [BEMA]
equivalent_PRED
to_PIN
the_DT
market_NN
value_NN
at_PIN
the_DT
date_NN
of_PIN
Statement_NOMZ
of_PIN
Financial_NN
Accounting_GER
Standards_NN
incremental_JJ
to_PIN
other_JJ
costs_NN
incurred_VBN [WZPAST]
by_PIN
the_DT
grant_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
cost_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
SFAS_NN
No._NN
._.
141_CD
Business_NOMZ
Combinations_NOMZ
and_PHC
company_NN
,_,
or_CC
represent_VB
amounts_NN
to_TO
be_VB
as_IN
the_DT
difference_NN
between_PIN
the_DT
option_NOMZ
price_NN
SFAS_NN
No._NN
._.
142_CD
Goodwill_NN
and_CC
Other_JJ
Intangible_JJ
incurred_VBN
under_IN
contractual_JJ
obligations_NOMZ
which_WDT [WHOBJ]
and_CC
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
or_CC
,_,
Assets_NN
were_VBD [PASS]
issued_VBN
in_PIN
July_NN
2001_CD
and_CC
are_VPRT
are_VPRT [PASS]
not_XX0
associated_VBN
with_PIN
or_CC
do_VB
not_XX0
benefit_VB
for_PIN
variable_JJ
plans_NN
,_,
at_PIN
the_DT
end_NN
of_PIN
the_DT
reporting_GER
effective_JJ
for_PIN
accounting_GER
periods_NN
commencing_VBG [WZPRES]
activities_NOMZ
that_TSUB
will_PRMD
be_VB [PASS]
continued_VBN
._.
Also_RB
,_,
all_QUAN
period_NN
until_IN
measurement_NOMZ
date_NN
._.
Under_IN
the_DT
on_PIN
or_CC
after_IN
15_CD
December_NN
2001_CD
._.
Under_IN
SFAS_NN
significant_JJ
actions_NOMZ
arising_VBG [WZPRES]
from_PIN
a_DT
restructuring_GER
requirements_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
141_CD
,_,
all_QUAN
business_NOMZ
combinations_NOMZ
initiated_VBN
and_CC
their_TPP3
completion_NOMZ
dates_NN
must_NEMD
be_VB [PASS]
identified_VBN
compensation_NOMZ
cost_NN
would_PRMD
be_VB [PASS]
amortised_VBN
over_IN
after_IN
30_CD
June_NN
2001_CD
must_NEMD
be_VB [PASS]
accounted_VBN
for_PIN
by_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
To_PIN
the_DT
extent_NN
that_TOBJ
the_DT
period_NN
from_PIN
the_DT
date_NN
the_DT
options_NOMZ
are_VPRT
using_VBG
the_DT
purchase_NN
method_NN
._.
The_DT
pooling_VBG
of_PIN
restructuring_GER
costs_NN
are_VPRT [PASS]
related_VBN
to_PIN
the_DT
activities_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
the_DT
date_NN
they_TPP3
are_VPRT [BEMA]
first_JJ
exercisable_JJ
._.
interest_NN
method_NN
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
permitted_VBN
._.
of_PIN
the_DT
acquired_VBN
company_NN
,_,
US_FPP1
GAAP_NN
allows_VPRT [SUAV]
Under_IN
US_FPP1
GAAP_NN
in_PIN
the_DT
net_JJ
income_NN
Intangible_JJ
assets_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
are_VPRT [BEMA]
them_TPP3
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
a_DT
liability_NOMZ
upon_PIN
reconciliation_NOMZ
,_,
the_DT
Group_NN
has_VPRT [PEAS]
adjusted_VBN
for_PIN
required_VBN [SUAV]
to_TO
be_VB [PASS]
amortised_VBN
to_PIN
residual_JJ
values_NN
acquisition_NOMZ
._.
stock_NN
compensation_NOMZ
costs_NN
and_CC
calculated_VBN [PRIV]
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
lives_NN
unless_COND
they_TPP3
under_IN
APB_NN
Opinion_NN
No._NN
._.
25_CD
._.
are_VPRT [PASS]
regarded_VBN
as_IN
having_VBG
indefinite_JJ
useful_JJ
lives_NN
,_,
Software_NN
costs_NN
in_PIN
which_WDT [PIRE]
case_NN
they_TPP3
are_VPRT [PASS]
tested_VBN
annually_RB
for_PIN
Under_IN
UK_NN
GAAP_NN
,_,
AstraZeneca_NN
capitalises_VPRT
Statement_NOMZ
of_PIN
cash_NN
flows_NN
:_:
Basis_NN
of_PIN
impairment_NOMZ
._.
Goodwill_NN
,_,
arising_VBG [PRESP]
on_PIN
a_DT
certain_JJ
defined_VBN
software_NN
costs_NN
._.
Under_IN
US_FPP1
preparation_NOMZ
combination_NOMZ
of_PIN
business_NOMZ
,_,
is_VPRT [PASS]
tested_VBN
for_PIN
GAAP_NN
software_NN
costs_NN
are_VPRT
generally_RB
AstraZenecas_NN
Statement_NOMZ
of_PIN
Group_NN
Cash_NN
impairment_NOMZ
annually_RB
in_PIN
lieu_NN
of_PIN
amortisation_NOMZ
._.
capitalized_JJ
and_PHC
amortised_JJ
over_IN
three_CD
to_PIN
five_CD
Flow_NN
is_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
United_NN
SFAS_NN
No._NN
._.
142_CD
requires_VPRT [SUAV]
that_THVC
goodwill_NN
and_PHC
years_NN
._.
Kingdom_NN
Financial_NN
Reporting_GER
Standard_NN
1_CD
intangible_JJ
assets_NN
acquired_VBN [WZPAST]
prior_RB
to_PIN
1_CD
July_NN
2001_CD
Revised_VBN
1996_CD
FRS_NN
1_CD
,_,
whose_WPS
objective_NN
should_NEMD
continue_VB
to_TO
be_VB [PASS]
amortised_VBN
and_PHC
tested_VBN
Foreign_JJ
exchange_NN
and_PHC
principles_NN
are_VPRT [BEMA]
similar_PRED
to_PIN
those_DEMP
set_VBN
out_PIN
in_PIN
for_PIN
impairment_NOMZ
until_IN
the_DT
adoption_NOMZ
of_PIN
the_DT
Under_IN
UK_NN
GAAP_NN
,_,
unrealised_JJ
gains_NN
and_PHC
losses_NN
SFAS_NN
No._NN
._.
142_CD
an_DT
on_PIN
foreign_JJ
currency_NN
transactions_NOMZ
to_TO
hedge_VB
The_DT
principal_JJ
differences_NN
between_PIN
the_DT
impairment_NOMZ
test_NN
must_NEMD
be_VB [PASS]
carried_VBN
out_PIN
on_PIN
all_QUAN
anticipated_VBN [PRIV]
,_,
but_CC
not_XX0
firmly_RB
committed_VBN
,_,
foreign_JJ
standards_NN
relate_VPRT
to_PIN
classification_NOMZ
._.
Under_IN
FRS_NN
intangible_JJ
assets_NN
with_PIN
indefinite_JJ
useful_JJ
lives_NN
currency_NN
transactions_NOMZ
may_POMD
be_VB [PASS]
deferred_VBN
and_CC
1_CD
,_,
the_DT
Company_NN
presents_VPRT
its_PIT
cash_NN
flows_VPRT
for_PIN
a_DT
and_CC
goodwill_NN
._.
Any_QUAN
impairment_NOMZ
loss_NN
identified_VBN
accounted_VBD
for_PIN
at_PIN
the_DT
same_JJ
time_NN
as_IN
the_DT
operating_GER
activities_NOMZ
:_:
b_NN
dividends_NN
received_VBN [WZPAST]
on_PIN
the_DT
date_NN
of_PIN
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
Under_IN
US_FPP1
GAAP_NN
from_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
:_:
c_NN
returns_NN
should_NEMD
be_VB [PASS]
accounted_VBN
for_PIN
as_IN
a_DT
cumulative_JJ
such_JJ
deferral_NN
is_VPRT [PASS]
not_XX0
permitted_VBN
except_PIN
in_PIN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
:_:
d_LS
effect_NN
of_PIN
a_DT
change_NN
in_PIN
accounting_GER
principle_NN
._.
tax_NN
paid_VBN
:_:
e_LS
capital_NN
expenditure_NN
and_CC
financial_JJ
At_PIN
the_DT
same_JJ
time_NN
,_,
the_DT
estimated_VBN [PRIV]
useful_JJ
lives_NN
investment_NOMZ
:_:
f_LS
acquisitions_NOMZ
and_PHC
disposals_NN
:_:
g_NN
of_PIN
amortised_JJ
intangible_JJ
assets_NN
must_NEMD
be_VB [BEMA]
Derivative_JJ
instruments_NOMZ
and_CC
hedging_VBG
dividends_NN
paid_VBN [WZPAST]
to_PIN
shareholders_NN
:_:
h_VB
reviewed_VBN
._.
activities_NOMZ
management_NOMZ
of_PIN
liquid_JJ
resources_NN
:_:
and_ANDC
i_FPP1
Under_IN
US_FPP1
GAAP_NN
,_,
all_QUAN
derivative_JJ
instruments_NOMZ
financing_GER
._.
95_CD
requires_VPRT [SUAV]
only_DWNT
three_CD
Adoption_NOMZ
of_PIN
these_DEMO
new_JJ
accounting_GER
standards_NN
should_NEMD
be_VB [PASS]
recognized_VBN [PRIV]
as_IN
assets_NN
or_CC
liabilities_NOMZ
in_PIN
categories_NN
of_PIN
cash_NN
flow_NN
activity_NOMZ
being_VBG [WZPRES] [BEMA]
a_DT
has_VPRT [PEAS]
resulted_VBN
in_PIN
an_DT
estimated_VBN [PRIV]
increase_NN
in_PIN
net_JJ
the_DT
balance_NN
sheet_NN
at_PIN
fair_JJ
value_NN
._.
Gains_NN
and_PHC
operating_GER
:_:
b_NN
investing_GER
:_:
and_ANDC
c_NN
financing_GER
._.
income_NN
of_PIN
$_$
755m_CD
including_VBG
amortisation_NOMZ
losses_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
in_PIN
net_JJ
income_NN
unless_COND
charged_VBN
under_IN
UK_NN
GAAP_NN
of_PIN
$_$
55m_CD
._.
Initial_JJ
they_TPP3
are_VPRT [PASS]
regarded_VBN
as_IN
hedges_NN
._.
Under_IN
UK_NN
Cash_NN
flows_VPRT
from_PIN
taxation_NOMZ
,_,
returns_NN
on_PIN
adoption_NOMZ
of_PIN
SFAS_NN
No._NN
._.
142_CD
did_VBD
not_XX0
result_VB
in_PIN
an_DT
GAAP_NN
,_,
these_DEMO
instruments_NOMZ
are_VPRT [PASS]
measured_VBN
at_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
and_PHC
impairment_NOMZ
charge_NN
,_,
nor_SYNE
was_VBD
there_EX
any_QUAN
cost_NN
and_PHC
gains_NN
or_CC
losses_NN
deferred_VBN
until_IN
the_DT
dividends_NN
received_VBD
from_PIN
joint_JJ
ventures_NN
and_PHC
impairment_NOMZ
at_PIN
the_DT
subsequent_JJ
annual_JJ
test_NN
._.
associates_NN
under_IN
FRS_NN
1_CD
would_PRMD
be_VB [PASS]
included_VBN
as_IN
Had_VBD
goodwill_NN
not_XX0
been_VBN [PASS]
amortised_VBN
in_PIN
2001_CD
,_,
net_JJ
operating_GER
activities_NOMZ
under_IN
SFAS_NN
No._NN
._.
95_CD
:_:
income_NN
would_PRMD
have_VB [PEAS]
increased_VBN
from_PIN
$_$
1,397_CD
m_NN [BEMA]
Deferred_JJ
income_NN
capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
to_TO
$_$
2,125_CD
m_NN [BEMA]
2000_CD
$_$
865m_CD
to_TO
$_$
1,716_CD
m_NN [BEMA]
with_PIN
a_DT
Under_IN
UK_NN
GAAP_NN
,_,
profits_NN
or_CC
losses_NN
from_PIN
the_DT
and_CC
acquisitions_NOMZ
and_PHC
disposals_NN
would_PRMD
be_VB [BEMA]
corresponding_JJ
increase_NN
in_PIN
basic_JJ
and_PHC
diluted_JJ
sale_NN
of_PIN
product_NN
related_VBN
intangible_JJ
assets_NN
are_VPRT [PASS]
included_VBN
as_IN
investing_VBG
activities_NOMZ
:_:
and_ANDC
earnings_GER
per_PIN
share_NN
from_PIN
$_$
0.77_CD
to_TO
$_$
1.21_CD
2000_CD
classified_VBN
in_PIN
other_JJ
operating_GER
income_NN
and_CC
are_VPRT
distributions_NOMZ
would_PRMD
be_VB [PASS]
included_VBN
as_IN
a_DT
financing_GER
$_$
0.49_CD
to_TO
$_$
0.97_CD
._.
No_SYNE
changes_NN
were_VBD [PASS]
made_VBN
to_TO
stated_VBN [PUBV]
after_IN
taking_VBG
account_NN
of_PIN
product_NN
activity_NOMZ
under_IN
SFAS_NN
No._NN
._.
Under_IN
FRS_NN
1_CD
estimated_VBD [PRIV]
useful_JJ
lives_NN
of_PIN
intangible_JJ
assets_NN
._.
disposal_NN
costs_NN
and_PHC
costs_NN
of_PIN
minor_JJ
cash_NN
comprises_VPRT
cash_NN
in_PIN
hand_NN
and_PHC
deposits_NN
outstanding_JJ
obligations_NOMZ
._.
Under_IN
US_FPP1
GAAP_NN
,_,
repayable_JJ
on_PIN
demand_NN
,_,
less_JJ
overdrafts_NN
SFAS_NN
No._NN
._.
144_CD
Accounting_GER
for_PIN
the_DT
such_JJ
profits_NN
are_VPRT [PASS]
deferred_VBN
and_PHC
recognized_VBN [PRIV]
in_PIN
repayable_JJ
on_PIN
demand_NN
:_:
and_ANDC
liquid_JJ
resources_NN
Impairment_NOMZ
or_CC
Disposal_NN
of_PIN
Long-Lived_NN
Assets_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
www_NN
._.
com_NN
115_CD
addresses_NN
financial_JJ
accounting_GER
and_CC
reporting_VBG [PUBV]
for_PIN
the_DT
impairment_NOMZ
or_CC
disposal_NN
of_PIN
long-lived_JJ
assets_NN
and_PHC
supersedes_NN
SFAS_NN
No._NN
._.
121_CD
,_,
Accounting_GER
for_PIN
the_DT
Impairment_NOMZ
of_PIN
Long-Lived_NN
Assets_NN
and_CC
for_PIN
Long-Lived_NN
Assets_NN
to_TO
be_VB [PASS]
Disposed_VBN
of_PIN
and_CC
the_DT
accounting_GER
and_PHC
reporting_GER
provisions_NN
of_PIN
APB_NN
Opinion_NN
No._NN
._.
30_CD
,_,
Reporting_GER
the_DT
Results_NN
of_PIN
Operations_NOMZ
Reporting_GER
the_DT
Effects_NN
of_PIN
Disposal_NN
of_PIN
a_DT
Segment_NOMZ
of_PIN
a_DT
Business_NOMZ
,_,
and_ANDC
Extraordinary_JJ
,_,
Unusual_JJ
and_CC
Infrequently_NN
Occurring_GER
Events_NN
and_PHC
Transactions_NOMZ
,_,
for_PIN
the_DT
disposal_NN
of_PIN
a_DT
segment_NOMZ
of_PIN
a_DT
business_NOMZ
._.
It_PIT
is_VPRT [BEMA]
effective_PRED
for_PIN
accounting_GER
periods_NN
beginning_VBG [WZPRES]
on_PIN
or_CC
after_IN
15_CD
December_NN
2001_CD
._.
144_CD
did_VBD
not_XX0
have_VB
a_DT
material_NN
effect_NN
._.
New_NN
accounting_GER
standards_NN
not_XX0
yet_RB
adopted_VBN
SFAS_NN
No._NN
._.
143_CD
Accounting_GER
for_PIN
Asset_NN
Retirement_NOMZ
Obligation_NOMZ
addresses_VPRT
the_DT
accounting_GER
and_CC
reporting_VBG [PUBV]
for_PIN
obligations_NOMZ
associated_VBN [WZPAST]
with_PIN
the_DT
retirement_NOMZ
of_PIN
long-lived_JJ
assets_NN
and_CC
the_DT
associated_VBN
asset_NN
retirement_NOMZ
costs_NN
._.
It_PIT
is_VPRT [BEMA]
effective_PRED
for_PIN
accounting_GER
periods_NN
beginning_VBG [WZPRES]
on_PIN
or_CC
after_IN
15_CD
June_NN
2002_CD
._.
143_CD
is_VPRT [PASS]
not_XX0
expected_VBN [PRIV]
to_TO
have_VB
a_DT
material_NN
effect_NN
._.
146_CD
Accounting_GER
for_PIN
Costs_NN
Associated_NN
with_PIN
Exit_NN
or_CC
Disposal_NN
Activities_NOMZ
,_,
issued_VBN [PASTP]
on_PIN
30_CD
July_NN
2002_CD
requires_VPRT [SUAV] [THATD]
costs_NN
associated_VBN [WZPAST]
with_PIN
exit_NN
or_CC
disposal_NN
activities_NOMZ
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
the_DT
costs_NN
are_VPRT [PASS]
incurred_VBN
rather_RB
than_PIN
at_PIN
the_DT
date_NN
of_PIN
commitment_NOMZ
to_PIN
an_DT
exit_NN
or_CC
disposal_NN
plan_NN
._.
The_DT
provisions_NN
are_VPRT [BEMA]
effective_PRED
for_PIN
disposals_NN
initialised_VBN
after_IN
31_CD
December_NN
2002_CD
and_CC
restatement_NOMZ
of_PIN
prior_JJ
periods_NN
is_VPRT [PASS]
not_XX0
required_VBN [SUAV]
._.
146_CD
may_POMD
apply_VB
to_PIN
future_JJ
activities_NOMZ
which_WDT [WHSUB]
are_VPRT [PASS]
not_XX0
currently_RB
envisaged_VBN
it_PIT
is_VPRT [BEMA]
not_XX0
possible_PRED
to_TO
assess_VB
the_DT
impact_NN
of_PIN
SFAS_NN
No._NN
._.
148_CD
Accounting_GER
for_PIN
Stock_NN
Based_VBD
Compensation_NOMZ
Transition_NOMZ
and_PHC
Disclosure_NN
an_DT
amendment_NOMZ
of_PIN
FASB_NN
Statement_NOMZ
No._NN
._.
123_CD
permits_VPRT
two_CD
additional_JJ
transition_NOMZ
methods_NN
for_PIN
entities_NOMZ
that_TSUB
adopt_VPRT
the_DT
fair_JJ
value_NN
based_VBN
method_NN
of_PIN
accounting_GER
for_PIN
stock-based_JJ
employee_NN
compensation_NOMZ
._.
The_DT
Statement_NOMZ
also_RB
requires_VPRT [SUAV]
new_JJ
disclosures_NN
about_IN
the_DT
ramp-up_JJ
effect_NN
of_PIN
stock-based_JJ
employee_NN
compensation_NOMZ
on_PIN
reported_VBN [PUBV]
results_NN
and_CC
that_THVC
those_DEMO
effects_NN
be_VB [PASS]
disclosed_VBN [PUBV]
more_EMPH
prominently_RB
by_PIN
specifying_VBG
the_DT
form_NN
,_,
content_NN
and_PHC
location_NOMZ
of_PIN
those_DEMO
disclosures_NN
._.
The_DT
transition_NOMZ
guidance_NN
and_CC
annual_JJ
disclosure_NN
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
148_CD
are_VPRT [BEMA]
effective_PRED
for_PIN
fiscal_JJ
years_NN
ending_VBG [WZPRES]
after_IN
15_CD
December_NN
2002_CD
._.
AstraZeneca_NN
has_VPRT [PEAS]
not_XX0
yet_RB
determined_VBN [SUAV] [PRIV]
whether_IN [WHCL]
it_PIT
will_PRMD
adopt_VB
the_DT
transition_NOMZ
provisions_NN
of_PIN
SFAS_NN
No._NN
._.
com_NN
116_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Introduction_NOMZ
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
significant_JJ
difference_NN
between_PIN
the_DT
UK_NN
GAAP_NN
and_PHC
US_FPP1
GAAP_NN
treatment_NOMZ
of_PIN
the_DT
combination_NOMZ
of_PIN
Astra_NN
and_PHC
Zeneca_NN
in_PIN
the_DT
year_NN
of_PIN
acquisition_NOMZ
,_,
and_ANDC
in_PIN
the_DT
results_NN
of_PIN
preceding_VBG
periods_NN
,_,
condensed_JJ
statements_NOMZ
of_PIN
operations_NOMZ
and_PHC
cash_NN
flow_NN
under_IN
US_FPP1
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
the_DT
benefit_NN
of_PIN
US_FPP1
investors_NN
._.
The_DT
following_GER
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
the_DT
material_NN
adjustments_NOMZ
to_PIN
net_JJ
income_NN
and_PHC
shareholders_NN
equity_NOMZ
which_WDT [WHSUB]
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
As_IN
noted_VBN [PRIV]
on_PIN
page_NN
62_CD
,_,
2001_CD
and_CC
2000_CD
net_JJ
income_NN
and_PHC
shareholders_NN
equity_NOMZ
under_IN
UK_NN
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
under_IN
FRS19_NN
Deferred_NN
Tax_NN
._.
On_PIN
this_DEMO
basis_NN
the_DT
deferred_JJ
tax_NN
adjustment_NOMZ
below_PLACE
as_RB
been_VBN [PASS]
restated_VBN
for_PIN
those_DEMO
years_NN
._.
Net_JJ
income_NN
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
,_,
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
consolidated_JJ
statements_NOMZ
of_PIN
income_NN
before_IN
exceptional_JJ
items_NN
restated_VBN
3,186_CD
3,044_CD
2,858_CD
Exceptional_JJ
items_NN
after_IN
tax_NN
350 138 581_CD
Net_JJ
income_NN
for_PIN
the_DT
period_NN
under_IN
UK_NN
GAAP_NN
restated_VBD
2,836_CD
2,906_CD
2,277_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
US_FPP1
GAAP_NN
Purchase_NN
accounting_GER
adjustments_NOMZ
including_VBG [WZPRES]
goodwill_NN
and_CC
intangibles_VPRT
Deemed_JJ
acquisition_NOMZ
of_PIN
Astra_NN
Amortisation_NOMZ
and_CC
other_JJ
acquisition_NOMZ
adjustments_NOMZ
864_CD
1,514_CD
1,756_CD
Others_NN
55_CD
20_CD
Capitalisation_NOMZ
,_,
less_JJ
disposals_NN
and_PHC
amortisation_NOMZ
of_PIN
interest_NN
46_CD
57_CD
45_CD
Deferred_JJ
taxation_NOMZ
On_PIN
fair_JJ
values_NN
of_PIN
Astra_NN
239 249 284_CD
Others_NN
restated_VBN
99 198 115_CD
Pension_NN
expense_NN
50_CD
33_CD
50_CD
Post-retirement_NOMZ
benefits_NN
plan_VPRT
amendment_NOMZ
4_CD
44_CD
Software_NN
costs_NN
46_CD
10_CD
98_CD
Restructuring_GER
costs_NN
22_CD
97_CD
Share_NN
based_VBN
compensation_NOMZ
33_CD
7_CD
33_CD
Fair_NN
value_NN
of_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
93_CD
18_CD
Deferred_JJ
income_NN
recognition_NOMZ
61_CD
75_CD
Unrealised_JJ
losses_NN
on_PIN
foreign_JJ
exchange_NN
and_PHC
others_NN
1_CD
10_CD
2_CD
Net_JJ
income_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
policy_NN
2,307_CD
1,365_CD
865_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
policy_NN
,_,
net_NN
of_PIN
tax_NN
,_,
on_PIN
adoption_NOMZ
of_PIN
SFAS_NN
No_NN
133_CD
32_CD
Net_JJ
income_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
2,307_CD
1,397_CD
865_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
www_NN
._.
com_NN
117_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
US_FPP1
GAAP_NN
Condensed_NN
Consolidated_NN
Statement_NOMZ
of_PIN
Operations_NOMZ
2002 2001 2000_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Sales_NN
17,841_CD
16,222_CD
15,583_CD
Cost_NN
of_PIN
sales_NN
4,520_CD
4,198_CD
3,960_CD
Distribution_NOMZ
costs_NN
141 122 210_CD
Research_NN
and_PHC
development_NOMZ
3,069_CD
2,687_CD
2,620_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
6,165_CD
5,219_CD
4,861_CD
Acquisition_NOMZ
related_VBN
costs_NN
224_CD
419_CD
Amortisation_NOMZ
of_PIN
intangibles_NN
and_PHC
goodwill_NN
1,052_CD
1,769_CD
2,043_CD
Other_JJ
income_NN
308 283 223_CD
Operating_GER
income_NN
3,202_CD
2,286_CD
1,693_CD
Net_JJ
interest_NN
income_NN
140 188 183_CD
Income_NN
from_PIN
continuing_VBG
operations_NOMZ
before_IN
taxation_NOMZ
3,342_CD
2,474_CD
1,876_CD
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
1,035_CD
1,109_CD
969_CD
Net_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
2,307_CD
1,365_CD
907_CD
Discontinued_VBN
operations_NOMZ
:_:
Net_JJ
income_NN
from_PIN
discontinued_VBN
operations_NOMZ
42_CD
Net_JJ
income_NN
before_IN
cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
policy_NN
2,307_CD
1,365_CD
865_CD
Cumulative_JJ
effect_NN
of_PIN
change_NN
in_PIN
accounting_GER
policy_NN
on_PIN
adoption_NOMZ
of_PIN
SFAS_NN
No_NN
133_CD
32_CD
Net_JJ
income_NN
for_PIN
the_DT
year_NN
2,307_CD
1,397_CD
865_CD
Weighted_JJ
average_JJ
number_NN
of_PIN
$_$
0.25_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
of_PIN
shares_NN
1,733_CD
1,758_CD
1,768_CD
Dilutive_JJ
impact_NN
of_PIN
share_NN
options_NOMZ
outstanding_JJ
millions_NN
of_PIN
shares_NN
2_CD
32_CD
Diluted_VBN
weighted_JJ
average_JJ
number_NN
of_PIN
$_$
0.25_CD
Ordinary_NN
Shares_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
millions_NN
of_PIN
shares_NN
1,735_CD
1,761_CD
1,770_CD
Net_JJ
income_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
before_IN
change_NN
in_PIN
accounting_GER
policy_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_PHC
diluted_JJ
$_$
$_$
1.33_CD
$_$
0.77_CD
$_$
0.49_CD
Net_JJ
income_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
after_IN
change_NN
in_PIN
accounting_GER
policy_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_PHC
diluted_JJ
$_$
$_$
1.33_CD
$_$
0.79_CD
$_$
0.49_CD
2002 2001 2000_CD
Net_JJ
income_NN
from_PIN
continuing_VBG
operations_NOMZ
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_PHC
diluted_JJ
$_$
$_$
1.33_CD
$_$
0.79_CD
$_$
0.51_CD
Net_JJ
loss_NN
from_PIN
discontinued_VBN
operations_NOMZ
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_PHC
diluted_JJ
$_$
$_$
0.02_CD
The_DT
dividend_NN
in_PIN
specie_NN
in_PIN
2000_CD
in_PIN
respect_NN
of_PIN
the_DT
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
under_IN
US_FPP1
GAAP_NN
amounted_VBD
to_TO
$_$
836m_CD
,_,
after_IN
realized_VBN [PRIV]
exchange_NN
gains_NN
on_PIN
the_DT
translation_NOMZ
of_PIN
foreign_JJ
currency_NN
financial_JJ
statements_NOMZ
of_PIN
$_$
297m_CD
._.
As_IN
noted_VBN [PRIV]
on_PIN
page_NN
62_CD
,_,
cash_NN
settlement_NOMZ
discounts_NN
have_VPRT [PEAS]
been_VBN [PASS]
reclassified_VBN
from_PIN
cost_NN
of_PIN
sales_NN
to_PIN
sales_NN
._.
Comparative_JJ
information_NOMZ
for_PIN
2001_CD
and_CC
2000_CD
has_VPRT [SPAU] [PEAS]
also_RB
been_VBN [PASS]
reclassified_VBN
for_PIN
consistency_NN
of_PIN
presentation_NOMZ
._.
com_NN
118_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
US_FPP1
GAAP_NN
Statement_NOMZ
of_PIN
Comprehensive_NN
Income_NN
2002 2001 2000_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
for_PIN
the_DT
year_NN
2,307_CD
1,397_CD
865_CD
Exchange_NN
gains_NN
losses_NN
net_NN
of_PIN
tax_NN
2,919_CD
1,473_CD
2,184_CD
Exchange_NN
realized_VBD [PRIV]
on_PIN
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
297_CD
Other_JJ
movements_NOMZ
73_CD
2_CD
Total_JJ
Comprehensive_NN
Income_NN
5,153_CD
76_CD
1,618_CD
Other_JJ
movements_NOMZ
in_PIN
2002_CD
include_VPRT
the_DT
recognition_NOMZ
of_PIN
a_DT
minimum_JJ
liability_NOMZ
under_IN
SFAS_NN
87_CD
of_PIN
$_$
45m_CD
._.
The_DT
cumulative_JJ
exchange_NN
gains_NN
and_PHC
losses_NN
net_NN
of_PIN
tax_NN
on_PIN
the_DT
translation_NOMZ
of_PIN
foreign_JJ
currency_NN
financial_JJ
statements_NOMZ
under_IN
US_FPP1
GAAP_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
following_JJ
note_NN
:_:
2002 2001 2000_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Balance_NN
at_PIN
1_CD
January_NN
4,318_CD
2,845_CD
364_CD
Movement_NOMZ
in_PIN
year_NN
2,919_CD
1,473_CD
2,481_CD
Balance_NN
at_PIN
31_CD
December_NN
1,399_CD
4,318_CD
2,845_CD
Stock_NN
compensation_NOMZ
In_PIN
the_DT
Groups_NN
financial_JJ
statements_NOMZ
prepared_VBN
under_IN
UK_NN
GAAP_NN
,_,
no_SYNE
cost_NN
is_VPRT [PASS]
accrued_VBN
for_PIN
the_DT
share_NN
options_NOMZ
awarded_VBN [WZPAST]
to_PIN
employees_NN
under_IN
the_DT
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
,_,
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
,_,
and_ANDC
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
as_IN
the_DT
exercise_NN
price_NN
is_VPRT [BEMA]
equivalent_PRED
to_PIN
the_DT
market_NN
value_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Under_IN
US_FPP1
GAAP_NN
the_DT
cost_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
difference_NN
between_PIN
the_DT
option_NOMZ
price_NN
and_CC
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
or_CC
,_,
for_PIN
variable_JJ
plans_NN
,_,
at_PIN
the_DT
end_NN
of_PIN
the_DT
reporting_GER
period_NN
until_IN
measurement_NOMZ
date_NN
._.
Under_IN
the_DT
requirements_NOMZ
of_PIN
APB_NN
Opinion_NN
No._NN
._.
25_CD
any_QUAN
compensation_NOMZ
cost_NN
would_PRMD
be_VB [PASS]
amortised_VBN
over_IN
the_DT
period_NN
from_PIN
the_DT
date_NN
the_DT
options_NOMZ
are_VPRT [PASS]
granted_VBN [SUAV]
to_PIN
the_DT
date_NN
they_TPP3
are_VPRT [BEMA]
first_JJ
exercisable_JJ
._.
Under_IN
US_FPP1
GAAP_NN
in_PIN
the_DT
net_JJ
income_NN
reconciliation_NOMZ
,_,
the_DT
Group_NN
has_VPRT [PEAS]
adjusted_VBN
for_PIN
stock_NN
compensation_NOMZ
costs_NN
as_IN
calculated_VBN [PRIV]
under_IN
APB_NN
Opinion_NN
No_NN
25_CD
,_,
SFAS_NN
No._NN
._.
123_CD
sets_NN
out_PIN
an_DT
alternative_JJ
methodology_NN
for_PIN
recognizing_VBG [PRIV]
the_DT
compensation_NOMZ
cost_NN
based_VBN [WZPAST]
on_PIN
the_DT
fair_JJ
value_NN
at_PIN
grant_NN
date_NN
._.
Had_VBD
the_DT
Group_NN
adopted_VBD
this_DEMO
methodology_NN
,_,
the_DT
incremental_JJ
effect_NN
on_PIN
net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
is_VPRT [PASS]
shown_VBN [PRIV]
below_PLACE
:_:
2002 2001 2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
income_NN
under_IN
US_FPP1
GAAP_NN
as_IN
reported_VBN [PUBV]
2,307_CD
1,397_CD
865_CD
Compensation_NOMZ
cost_NN
after_IN
adjusting_VBG
for_PIN
APB_NN
25_CD
credit_NN
of_PIN
$_$
33m_CD
155_CD
76_CD
46_CD
Pro_PIN
forma_FW
net_JJ
income_NN
2,152_CD
1,321_CD
819_CD
Pro_PIN
forma_FW
net_JJ
income_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
and_PHC
ADS_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
basic_JJ
and_CC
diluted_VBN
:_:
As_IN
reported_VBN [PUBV]
$_$
$_$
1.33_CD
$_$
0.79_CD
$_$
0.49_CD
Pro_PIN
forma_FW
$_$
$_$
1.24_CD
$_$
0.75_CD
$_$
0.46_CD
The_DT
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
is_VPRT [PASS]
estimated_VBN [PRIV]
,_,
based_VBN [PASTP]
on_PIN
the_DT
stock_NN
price_NN
at_PIN
the_DT
grant_NN
date_NN
,_,
using_VBG [PRESP]
the_DT
Black-Scholes_NN
option_NOMZ
pricing_GER
model_NN
with_PIN
the_DT
following_VBG
assumptions_NOMZ
:_:
2002 2001 2000_CD
Dividend_NN
yield_NN
1.6_CD
%_NN
1.5_CD
%_NN
2.0_CD
%_NN
Expected_VBN [PRIV]
volatility_NOMZ
30.0_CD
%_NN
20.0_CD
%_NN
20.0_CD
%_NN
Risk-free_JJ
interest_NN
rate_NN
5.2_CD
%_NN
4.2_CD
%_NN
5.9_CD
%_NN
Expected_VBN [PRIV]
lives_NN
:_:
1994_CD
Scheme_NN
6.0_CD
years_NN
Expected_VBN [PRIV]
lives_NN
:_:
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
6.0_CD
years_NN
6.0_CD
years_NN
6.0_CD
years_NN
Expected_VBN [PRIV]
lives_NN
:_:
SAYE_NN
Scheme_NN
4.3_CD
years_NN
4.3_CD
years_NN
4.6_CD
years_NN
In_PIN
the_DT
initial_JJ
phase-in_PIN
period_NN
,_,
the_DT
effects_NN
of_PIN
applying_VBG
SFAS_NN
No._NN
._.
123_CD
for_PIN
disclosing_VBG [PUBV]
compensation_NOMZ
cost_NN
may_POMD
not_XX0
be_VB
representative_NN
of_PIN
the_DT
effects_NN
on_PIN
pro_PIN
forma_FW
net_JJ
income_NN
and_PHC
earnings_GER
per_PIN
share_NN
for_PIN
future_JJ
years_NN
._.
com_NN
119_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
Pension_NN
and_PHC
post-retirement_NOMZ
benefits_NN
For_PIN
the_DT
purposes_NN
of_PIN
US_FPP1
GAAP_NN
,_,
the_DT
pension_NN
costs_NN
of_PIN
the_DT
major_JJ
UK_NN
retirement_NOMZ
plan_NN
and_CC
of_PIN
the_DT
retirement_NOMZ
plans_NN
of_PIN
the_DT
major_JJ
non-UK_JJ
subsidiaries_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
in_PIN
the_DT
following_VBG
tables_NN
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
SFAS_NN
No._NN
._.
These_DEMO
plans_NN
comprise_VPRT
a_DT
substantial_JJ
portion_NOMZ
of_PIN
the_DT
actuarial_JJ
liabilities_NOMZ
of_PIN
all_QUAN
AstraZeneca_NN
retirement_NOMZ
plans_NN
._.
The_DT
changes_NN
in_PIN
projected_VBN
benefit_NN
obligations_NOMZ
,_,
plan_NN
assets_NN
and_PHC
details_NN
of_PIN
the_DT
funded_JJ
status_NN
of_PIN
these_DEMO
retirement_NOMZ
plans_NN
,_,
together_RB
with_PIN
the_DT
changes_NN
in_PIN
the_DT
accumulated_VBN
other_JJ
post-retirement_JJ
benefit_NN
obligations_NOMZ
,_,
under_IN
SFAS_NN
No._NN
._.
132_CD
are_VPRT
as_IN
follows_VPRT
:_:
Other_JJ
post-retirement_JJ
Pension_NN
benefits_NN
benefits_NN
Change_NN
in_PIN
projected_VBN
benefit_NN
obligation_NOMZ
2002 2001 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Benefit_NN
obligation_NOMZ
at_PIN
beginning_GER
of_PIN
year_NN
4,337_CD
4,188_CD
205_CD
197_CD
Service_NN
cost_NN
114_CD
102_CD
8_CD
7_CD
Interest_NN
cost_NN
263_CD
243_CD
14_CD
14_CD
Participant_NN
contributions_NOMZ
18_CD
17_CD
Plan_NN
amendments_NOMZ
11_CD
Actuarial_JJ
gain_NN
loss_NN
80_CD
75_CD
23_CD
1_CD
Special_JJ
termination_NOMZ
benefits_NN
12_CD
19_CD
Settlement_NOMZ
and_PHC
curtailment_NOMZ
24_CD
Benefits_NN
paid_VBD
206_CD
198_CD
19_CD
14_CD
Exchange_NN
408_CD
98_CD
3_CD
2_CD
Benefit_NN
obligation_NOMZ
at_PIN
end_NN
of_PIN
year_NN
5,026_CD
4,337_CD
210_CD
205_CD
Other_JJ
post-retirement_NOMZ
Pension_NN
benefits_NN
benefits_NN
Change_NN
in_PIN
plan_NN
assets_NN
2002 2001 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Fair_NN
value_NN
at_PIN
1_CD
January_NN
3,753_CD
3,803_CD
Actual_JJ
return_NN
on_PIN
plan_NN
assets_NN
142_CD
45_CD
16_CD
Group_NN
contribution_NOMZ
284 170 161_CD
Participant_NN
contributions_NOMZ
18_CD
17_CD
Settlement_NOMZ
and_PHC
curtailment_NOMZ
Benefits_NN
paid_VBD
205_CD
198_CD
12_CD
Exchange_NN
330_CD
84_CD
Fair_NN
value_NN
of_PIN
plan_NN
assets_NN
at_PIN
end_NN
of_PIN
year_NN
4,038_CD
3,753_CD
133_CD
Funded_VBN
status_NN
of_PIN
plans_NN
988_CD
584_CD
77_CD
205_CD
Unrecognised_JJ
net_JJ
loss_NN
profit_NN
938_CD
396_CD
Prior_RB
service_NN
cost_NN
not_XX0
recognized_VBN [PRIV]
29_CD
35_CD
Unrecognised_JJ
net_JJ
obligation_NOMZ
on_PIN
implementation_NOMZ
3_CD
6_CD
18_CD
147_CD
77_CD
205_CD
Adjustments_NOMZ
to_TO
recognize_VB [PRIV]
minimum_JJ
liability_NOMZ
Intangible_JJ
assets_NN
45_CD
Accumulated_VBN
other_JJ
comprehensive_JJ
income_NN
45_CD
Accrued_VBN
benefit_NN
liability_NOMZ
108_CD
147_CD
77_CD
205_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
www_NN
._.
com_NN
120_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
At_PIN
31_CD
December_NN
2002_CD
,_,
the_DT
projected_VBN
benefit_NN
obligation_NOMZ
,_,
accumulated_VBN
benefit_NN
obligation_NOMZ
and_CC
fair_JJ
value_NN
of_PIN
the_DT
plan_NN
assets_NN
in_PIN
respect_NN
of_PIN
the_DT
retirement_NOMZ
plans_NN
above_PLACE
with_PIN
accumulated_VBN
benefit_NN
obligations_NOMZ
in_PIN
excess_NN
of_PIN
plan_NN
assets_NN
were_VBD
$_$
4,249_CD
m_NN
,_,
$_$
3,557_CD
m_NN
and_CC
$_$
3,296_CD
m_NN
,_,
2001_CD
$_$
97m_CD
,_,
$_$
73m_CD
and_CC
$_$
nil_JJ
respectively_RB
._.
Assumed_VBN [PRIV]
discount_NN
rates_NN
and_PHC
rates_NN
of_PIN
increase_NN
in_PIN
remuneration_NOMZ
used_VBN [WZPAST]
in_PIN
calculating_VBG [PRIV]
the_DT
projected_VBN
benefit_NN
obligations_NOMZ
together_RB
with_PIN
long_JJ
term_NN
rates_NN
of_PIN
return_NN
on_PIN
plan_NN
assets_NN
vary_VPRT
according_VBG
to_PIN
the_DT
economic_JJ
conditions_NOMZ
of_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
retirement_NOMZ
plans_NN
are_VPRT [PASS]
situated_VBN
._.
The_DT
weighted_JJ
average_NN
rates_NN
used_VBN [WZPAST]
for_PIN
calculation_NOMZ
of_PIN
year_NN
end_NN
benefit_NN
obligations_NOMZ
and_PHC
forecast_NN
benefit_NN
cost_NN
in_PIN
the_DT
main_JJ
retirement_NOMZ
plans_NN
and_CC
other_JJ
benefit_NN
obligations_NOMZ
for_PIN
SFAS_NN
No._NN
._.
132_CD
purposes_NN
were_VBD
as_IN
follows_VPRT
:_:
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2002 2001 2000 2002_CD
2001_CD
2000_CD
%_NN
%_NN
%_NN
%_NN
%_NN
%_NN
Discount_NN
rate_NN
5.8_CD
6.0_CD
5.6_CD
6.6_CD
7.1_CD
7.1_CD
Long_JJ
term_NN
rate_NN
of_PIN
increase_NN
in_PIN
remuneration_NOMZ
4.1_CD
4.4_CD
4.4_CD
4.8_CD
n_VBD
a_DT
n_NN
a_DT
Expected_VBN [PRIV]
long_JJ
term_NN
return_NN
on_PIN
assets_NN
6.4_CD
6.5_CD
6.2_CD
7.8_CD
n_VBD
a_DT
n_NN
a_DT
The_DT
Group_NN
has_VPRT [PEAS]
assumed_VBN [PRIV]
a_DT
long_JJ
term_NN
rate_NN
of_PIN
increase_NN
in_PIN
healthcare_NN
costs_NN
of_PIN
11.0_CD
%_NN
,_,
reducing_VBG [PRESP]
to_PIN
5.0_CD
%_NN
._.
Pension_NN
benefits_NN
Other_JJ
post-retirement_NOMZ
benefits_NN
2002 2001 2000 2002_CD
2001_CD
2000_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Net_JJ
periodic_JJ
cost_NN
Service_NN
cost_NN
present_JJ
value_NN
of_PIN
benefits_NN
accruing_VBG [WZPRES]
during_PIN
the_DT
year_NN
114 102 152_CD
8_CD
710_CD
Interest_NN
cost_NN
on_PIN
projected_VBN
benefit_NN
obligations_NOMZ
263 243 301_CD
14_CD
14_CD
17_CD
Expected_VBN [PRIV]
return_NN
on_PIN
assets_NN
263 242 322_CD
Net_JJ
amortisation_NOMZ
and_CC
deferral_JJ
28_CD
39_CD
46_CD
1_CD
2_CD
1_CD
Net_JJ
periodic_JJ
cost_NN
for_PIN
the_DT
year_NN
142 142 177_CD
21_CD
19_CD
26_CD
It_PIT
is_VPRT [PASS]
estimated_VBN [PRIV]
that_THVC
a_DT
1_CD
percentage_NN
point_NN
change_NN
in_PIN
the_DT
weighted_JJ
average_JJ
healthcare_NN
costs_NN
trend_NN
would_PRMD
have_VB
the_DT
following_JJ
effects_NN
on_PIN
the_DT
accumulated_VBN
benefit_NN
obligation_NOMZ
and_CC
net_JJ
periodic_JJ
cost_NN
at_PIN
31_CD
December_NN
2002_CD
:_:
1_CD
percentage_NN
point_NN
increase_NN
decrease_NN
$_$
m_CD
$_$
m_CD [PASS]
Accumulated_VBN
benefit_NN
obligation_NOMZ
10_CD
9_CD
Net_NN
periodic_JJ
cost_NN
2_CD
1_CD
Taxation_NOMZ
2002 2001 2000_CD
Years_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
UK_NN
taxation_NOMZ
Corporation_NOMZ
tax_NN
165_CD
147_CD
79_CD
Double_RB
taxation_NOMZ
relief_NN
7_CD
4_CD
42_CD
Deferred_VBN
40_CD
10_CD
27_CD
Overseas_PLACE
taxation_NOMZ
Overseas_PLACE
taxes_NN
921 831 956_CD
Deferred_JJ
taxation_NOMZ
84_CD
125_CD
Share_NN
of_PIN
taxation_NOMZ
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
3_CD
Taxes_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
1,035_CD
1,109_CD
969_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
www_NN
._.
com_NN
121_CD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
The_DT
table_NN
below_PLACE
reconciles_NN
the_DT
UK_NN
statutory_JJ
tax_NN
charge_NN
to_PIN
the_DT
Groups_NN
actual_JJ
charge_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
._.
2002 2001 2000_CD
Years_NN
ended_VBD
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Income_NN
on_PIN
continuing_VBG
operations_NOMZ
3,342_CD
2,506_CD
1,876_CD
Taxation_NOMZ
charge_NN
at_PIN
UK_NN
corporation_NOMZ
tax_NN
rate_NN
of_PIN
30_CD
%_NN
for_PIN
2002_CD
30_CD
%_NN
for_PIN
2001_CD
,_,
30_CD
%_NN
for_PIN
2000_CD
1,002_CD
751_CD
563_CD
Acquisition_NOMZ
related_VBN
items_NN
429_CD
Goodwill_NN
,_,
Advanta_NN
,_,
and_ANDC
Salick_NN
Health_NN
Care_NN
impairment_NOMZ
190_CD
576_CD
Net_JJ
effect_NN
of_PIN
different_JJ
rates_NN
and_CC
eligible_JJ
costs_NN
in_PIN
other_JJ
jurisdictions_NOMZ
21_CD
43_CD
86_CD
Exceptional_JJ
items_NN
105_CD
419_CD
Other_JJ
51 203 132_CD
Tax_NN
on_PIN
income_NN
from_PIN
continuing_VBG
operations_NOMZ
1,035_CD
1,109_CD
969_CD
In_PIN
2002_CD
,_,
claims_VPRT [PUBV]
amounting_VBG
to_TO
$_$
43m_CD
2001_CD
$_$
109m_CD
for_PIN
tax_NN
relief_NN
arising_VBG [WZPRES]
as_CONJ
a_NULL
result_NULL
of_PIN
a_DT
restructuring_GER
of_PIN
the_DT
AMI_NN
joint_JJ
venture_NN
in_PIN
1998_CD
were_VBD [PASS]
made_VBN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
these_DEMO
reliefs_NN
are_VPRT [PASS]
adjusted_VBN
against_PIN
the_DT
goodwill_NN
arising_VBG [WZPRES]
on_PIN
the_DT
restructuring_GER
and_CC
included_VBD
in_PIN
other_JJ
adjustments_NOMZ
._.
Shareholders_NN
equity_NOMZ
2002_CD
2001_CD
$_$
m_CD
$_$
m_CD [BEMA]
Total_JJ
shareholders_NN
equity_NOMZ
under_IN
UK_NN
GAAP_NN
restated_VBD
11,172_CD
9,586_CD
Adjustments_NOMZ
to_TO
conform_VB
to_PIN
US_FPP1
GAAP_NN
Purchase_NN
accounting_GER
adjustments_NOMZ
including_VBG [WZPRES]
goodwill_NN
and_CC
intangibles_VPRT
Deemed_JJ
acquisition_NOMZ
of_PIN
Astra_NN
Goodwill_NN
12,692_CD
11,062_CD
Tangible_JJ
and_PHC
intangible_JJ
fixed_VBN
assets_NN
7,707_CD
8,139_CD
Others_NN
86_CD
31_CD
Capitalisation_NOMZ
,_,
less_JJ
disposals_NN
and_PHC
amortisation_NOMZ
of_PIN
interest_NN
238_CD
192_CD
Deferred_JJ
taxation_NOMZ
On_PIN
fair_JJ
value_NN
of_PIN
Astra_NN
2,305_CD
2,313_CD
Others_NN
restated_VBN
159_CD
68_CD
Dividend_NN
808_CD
820_CD
Pension_NN
expense_NN
271_CD
162_CD
Post-retirement_NOMZ
benefits_NN
plan_VPRT
amendment_NOMZ
24_CD
28_CD
Software_NN
costs_NN
capitalized_JJ
64_CD
110_CD
Fair_NN
value_NN
of_PIN
derivative_JJ
financial_JJ
instruments_NOMZ
99_CD
50_CD
Deferred_JJ
income_NN
recognition_NOMZ
14_CD
75_CD
Others_NN
90_CD
58_CD
Shareholders_NN
equity_NOMZ
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
30,183_CD
27,402_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
www_NN
._.
com_NN
122_CD
Additional_JJ
Information_NOMZ
for_PIN
US_FPP1
Investors_NN
continued_VBD
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
accounting_GER
principles_NN
continued_VBD
US_FPP1
GAAP_NN
Condensed_NN
Consolidated_NN
Statement_NOMZ
of_PIN
Cash_NN
Flows_NN
2002 2001 2000_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cash_NN
flows_VPRT
from_PIN
operating_VBG
activities_NOMZ
4,833_CD
3,126_CD
3,554_CD
Cash_NN
flows_VPRT
from_PIN
investing_VBG
activities_NOMZ
Movement_NOMZ
in_PIN
short_JJ
term_NN
investments_NOMZ
and_CC
fixed_VBN
deposits_NN
806 260 608_CD
New_NN
fixed_JJ
asset_NN
investments_NOMZ
1_CD
5_CD
3_CD
Disposal_NN
of_PIN
fixed_JJ
assets_NN
66_CD
44_CD
37_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
44_CD
740_CD
Capital_NN
expenditure_NN
1,608_CD
1,582_CD
1,460_CD
Net_JJ
cash_NN
outflows_NN
from_PIN
investing_VBG
activities_NOMZ
2,349_CD
1,327_CD
1,294_CD
Net_JJ
cash_NN
flow_NN
before_IN
financing_VBG
2,484_CD
1,799_CD
2,260_CD
Cash_NN
flows_VPRT
from_PIN
financing_VBG
activities_NOMZ
Equity_NOMZ
dividends_NN
paid_VBD
1,234_CD
1,236_CD
1,220_CD
Repurchase_NN
of_PIN
AstraZeneca_NN
PLC_NN
Ordinary_NN
Shares_NN
1,154_CD
994_CD
334_CD
Net_JJ
decrease_NN
increase_NN
in_PIN
short_JJ
term_NN
borrowings_GER
13_CD
7_CD
67_CD
Loans_NN
repaid_VBN
new_JJ
loans_NN
105_CD
28_CD
3_CD
Repayment_NOMZ
of_PIN
lease_NN
finance_NN
2_CD
Net_JJ
cash_NN
outflows_NN
from_PIN
financing_VBG
activities_NOMZ
2,506_CD
2,195_CD
1,620_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
22 396 640_CD
Cash_NN
:_:
At_PIN
1_CD
January_NN
510 908 262_CD
Decrease_NN
increase_NN
in_PIN
cash_NN
22 396 640_CD
Exchange_NN
movements_NOMZ
36_CD
2_CD
6_CD
At_PIN
31_CD
December_NN
524 510 908_CD
1_CD
Interest_NN
paid_VBN [WZPAST]
was_VBD
$_$
96m_CD
in_PIN
2002_CD
,_,
$_$
84m_CD
in_PIN
2001_CD
,_,
$_$
145m_CD
in_PIN
2000_CD
._.
